In this video from the Macula Society meeting, Sunir J. Garg, MD, FACS, FASRS, of the retina service at Wills Eye Hospital, discusses 5-year fellow eye data on pegcetacoplan for geographic atrophy.“We found that if you use sham or projected sham, treatment with pegcetacoplan (Apellis) reduces disease progression by about 25% in the all-comer group,” Garg said. “That was even more significant if you look at patients who had baseline nonsubfoveal atrophy.”In addition, the fellow eye “almost mirrored sham precisely,” confirming that “two eyes and
